| Bioactivity | Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs)[1]. | ||||||
| In Vivo | Reltecimod (1.25-5 mg/kg; i.v.) TFA 可提高感染不同细菌的小鼠的存活率[1]。 | ||||||
| Name | Reltecimod TFA | ||||||
| Sequence | Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-Ala | ||||||
| Shortening | ASPMLVAYDA | ||||||
| Formula | C46H72N10O15S.xC2HF3O2 | ||||||
| Molar Mass | 1037.19 (free base) | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||
| Reference | [1]. Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020). |
Reltecimod TFA
CAS: F: C46H72N10O15S.xC2HF3O2 W: 1037.19 (free base)
Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.